Company intelligence / Profile preview

Mirum Pharmaceuticals, Inc.

Foster City, California, United Statesmirumpharma.com ↗

Ownership: Public · MIRM
Employees: ~311
Development stage: Commercial

Overview

Mirum has three FDA-approved medications: LIVMARLI (maralixibat) for cholestatic pruritus in ALGS and PFIC patients, CHOLBAM (cholic acid) for bile acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis. The company also has several late-stage pipeline candidates in development.

Therapeutic areas: GastroenterologyRare DiseasesNeurologyMetabolic Disorders
Modalities: Small moleculesGene therapyIBAT inhibitors
Industry: Biotech

Drug pipeline

7 assets

maralixibat

Approved

6 more assets in the full pipeline.

Request access →

Partnerships

Vivet Therapeutics

Financials

Market cap: $6.1B
Total revenue: $176.2M
Enterprise value: $6.5B

Beyond the preview

Go deeper on Mirum Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mirum Pharmaceuticals, Inc..

Explore the full profile